Knowledge Library

Engineered Oncolytic Viruses Expressing Immunomodulatory Genes Enhances In Vitro Anti-Tumor Cellular Immune Responses

While chemo- and radio-therapy are considered the first-line of treatment for most cancers, its serious side effects have led to continuous innovation and discovery of new anti-tumor treatments. Oncolytic viruses (OVs) possess a magnitude of mechanism of action to elicit anti-tumor immune response, including OVs innate cytotoxicity and enhanced anti-tumor immunity by inserting immunomodulatory genes. …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Biomarkers, Cell-based Assays, Immunology, in vitro biology, Oncology, Oncolytic Viruses, Phenotypic Assays, Target Identification and Validation

VIEW

How Does It Work? | Targeted Protein Degrader

As part of our dedication to providing an #openaccess platform, so our entire ecosystem can come together to share #science & #collaborate to better the lives of all #patientsfirst. We’ve created MoA animations in our new series exploring biotech topics on a molecular level. First up, we explain the intricacies of how targeted protein degradation …Read More >

Resource Type: Video
Resource Topic: Biochemical Assays, Biophysical Assays, Cell-based Assays, Oncology, Target Identification and Validation, Targeted Protein Degradation

VIEW

How Does It Work? | RNAi

As part of our dedication to providing an #openaccess platform, so our entire ecosystem can come together to share #science & #collaborate to better the lives of all #patientsfirst. We’ve created MoA animations in our new series exploring biotech topics on a molecular level. Protein malfunctions cause many diseases, but a new approach is emerging …Read More >

Resource Type: Video
Resource Topic: Autoimmune and Inflammatory Diseases, Cardiovascular & Metabolic Diseases, Central Nervous System & Pain, DRUG DISCOVERY AND INNOVATION, Gene Therapies, Liver Diseases, Metabolic Diseases, Oligonucleotides, Oncology, Ophthalmology, Rare Diseases, Target Identification and Validation

VIEW

OncoWuXi Newsletter: June 2022

WuXi AppTec xenograft and syngeneic tumor models in rats and CD47-related in vitro assay platform

Resource Type: Newsletter
Resource Topic: Antibodies, Cell-based Assays, Hit-to-Lead, in vivo Pharmacology, Lead Optimization, Oncology, Target-Specific Assays, Tumor Models

VIEW

WuXi AppTec Discovery Services

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.  

Resource Type: Brochure
Resource Topic: Antibodies, Antibody Drug Conjugate, Autoimmune and Inflammatory Diseases, Biochemical Assays, Biomarkers, Biophysical Assays, Candidate Selection, CAR-T Cell, Cardiovascular & Metabolic Diseases, Cell Therapies, Cell-based Assays, Cells and Protein Science, Central Nervous System & Pain, Chemical Biology and Proteomics, Dermatology, Discovery Chemistry, DNA-Encoded Library (DEL), DRUG DISCOVERY AND INNOVATION, Fragment-Based Drug Discovery, Gene Therapies, High-throughput screening (HTS), Hit Finding, Hit-to-Lead, Immunology, in silico services, in vitro biology, in vivo Pharmacology, in vivo Toxicology, Infectious Diseases, Lead Optimization, Liver Diseases, Mass Spectrometry-based Assays, Metabolic Diseases, NASH, Oligonucleotides, Oncology, Oncolytic Viruses, Ophthalmology, Phenotypic Assays, Quantum Mechanics, Rare Diseases, Respiratory Diseases, Safety and Early Toxicity, Screening Libraries, Screening Services, Small Molecules, Structural Biology, Target Identification and Validation, Target-Specific Assays, Targeted Protein Degradation, TECHNOLOGY PLATFORMS, THERAPEUTIC AREAS, THERAPEUTIC MODALITIES, Tumor Models

VIEW

Bone metastasis platform to evaluate prophylaxis and treatment

Resource Type: Presentation
Resource Topic: in vivo Pharmacology, Lead Optimization, Oncology, Small Molecules, Target Identification and Validation

VIEW

Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase

Structure-based design was utilized to optimize 6,6-diaryl substituted dihydropyrone and hydroxylactam to obtain inhibitors of lactate dehydrogenase (LDH) with low nanomolar biochemical and single-digit micromolar cellular potencies. Surprisingly the replacement of a phenyl with a pyridyl moiety in the chemical structure revealed a new binding mode for the inhibitors with subtle conformational change of the …Read More >

Resource Type: Publication
Resource Topic: Chemical Biology and Proteomics, Discovery Chemistry, Hit-to-Lead, Lead Optimization, Oncology, Small Molecules

VIEW

HIJACKING CELLULAR MECHANISMS TO TREAT COMPLEX DISEASES

Resource Type: White Paper
Resource Topic: Biochemical Assays, Biomarkers, Biophysical Assays, Cell-based Assays, DRUG DISCOVERY AND INNOVATION, in vitro biology, Oligonucleotides, Oncology, Rare Diseases, Target Identification and Validation, Target-Specific Assays, Targeted Protein Degradation

VIEW

Brain metastasis mouse models for the evaluation of multikinase inhibitors on ROS1-fusion-positive lung cancer

Lung cancer is the leading cause of cancer-related death worldwide.  Nearly 80% of lung cancers are non-small cell lung cancer (NSCLC) and 60% of them are diagnosed at the metastatic stage. Brain metastases affect more than 20% of NSCLC patients with poor prognosis and disabling symptoms. However, few therapies have been approved for the treatment …Read More >

Resource Type: Poster
Resource Topic: in vivo Pharmacology, Lead Optimization, Oncology, Small Molecules, Tumor Models

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!